nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO2A1—Furosemide—dilated cardiomyopathy	0.783	1	CbGbCtD
Alprostadil—PTGIR—pulmonary artery—dilated cardiomyopathy	0.0209	0.336	CbGeAlD
Alprostadil—Instillation site pain—Furosemide—dilated cardiomyopathy	0.00437	0.0456	CcSEcCtD
Alprostadil—SLCO3A1—cardiac ventricle—dilated cardiomyopathy	0.00383	0.0617	CbGeAlD
Alprostadil—SLCO2A1—cardiac ventricle—dilated cardiomyopathy	0.00379	0.0611	CbGeAlD
Alprostadil—SLCO3A1—myocardium—dilated cardiomyopathy	0.0036	0.058	CbGeAlD
Alprostadil—SLCO2A1—myocardium—dilated cardiomyopathy	0.00357	0.0574	CbGeAlD
Alprostadil—ABCC5—cardiac ventricle—dilated cardiomyopathy	0.00347	0.0559	CbGeAlD
Alprostadil—ABCC5—myocardium—dilated cardiomyopathy	0.00326	0.0525	CbGeAlD
Alprostadil—Application site pain—Furosemide—dilated cardiomyopathy	0.00324	0.0338	CcSEcCtD
Alprostadil—Diabetic—Lisinopril—dilated cardiomyopathy	0.0032	0.0334	CcSEcCtD
Alprostadil—Anuria—Lisinopril—dilated cardiomyopathy	0.00306	0.0319	CcSEcCtD
Alprostadil—PTGIR—heart—dilated cardiomyopathy	0.00285	0.0459	CbGeAlD
Alprostadil—Local reaction—Furosemide—dilated cardiomyopathy	0.00257	0.0269	CcSEcCtD
Alprostadil—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00257	0.0269	CcSEcCtD
Alprostadil—SLCO3A1—heart—dilated cardiomyopathy	0.00251	0.0405	CbGeAlD
Alprostadil—SLCO2A1—heart—dilated cardiomyopathy	0.00249	0.0401	CbGeAlD
Alprostadil—ABCC5—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00249	0.042	CbGpPWpGaD
Alprostadil—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.0024	0.0251	CcSEcCtD
Alprostadil—Leg pain—Lisinopril—dilated cardiomyopathy	0.00231	0.0242	CcSEcCtD
Alprostadil—ABCC5—heart—dilated cardiomyopathy	0.00228	0.0367	CbGeAlD
Alprostadil—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00217	0.0227	CcSEcCtD
Alprostadil—SLCO3A1—cardiac atrium—dilated cardiomyopathy	0.00215	0.0346	CbGeAlD
Alprostadil—SLCO2A1—cardiac atrium—dilated cardiomyopathy	0.00213	0.0343	CbGeAlD
Alprostadil—ABCC5—cardiac atrium—dilated cardiomyopathy	0.00195	0.0314	CbGeAlD
Alprostadil—Lethargy—Spironolactone—dilated cardiomyopathy	0.00194	0.0202	CcSEcCtD
Alprostadil—SLCO2B1—heart—dilated cardiomyopathy	0.00178	0.0287	CbGeAlD
Alprostadil—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00176	0.0183	CcSEcCtD
Alprostadil—Injection site pain—Furosemide—dilated cardiomyopathy	0.00174	0.0182	CcSEcCtD
Alprostadil—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00174	0.0181	CcSEcCtD
Alprostadil—ABCC4—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00172	0.0291	CbGpPWpGaD
Alprostadil—PTGIR—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.00162	0.0274	CbGpPWpGaD
Alprostadil—ABCC4—heart—dilated cardiomyopathy	0.00158	0.0254	CbGeAlD
Alprostadil—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.0015	0.0156	CcSEcCtD
Alprostadil—Renal failure—Spironolactone—dilated cardiomyopathy	0.00144	0.015	CcSEcCtD
Alprostadil—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.0014	0.0146	CcSEcCtD
Alprostadil—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00131	0.0137	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00122	0.0207	CbGpPWpGaD
Alprostadil—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00121	0.0126	CcSEcCtD
Alprostadil—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00119	0.0124	CcSEcCtD
Alprostadil—Swelling—Furosemide—dilated cardiomyopathy	0.00117	0.0122	CcSEcCtD
Alprostadil—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0011	0.0115	CcSEcCtD
Alprostadil—Lethargy—Furosemide—dilated cardiomyopathy	0.00105	0.011	CcSEcCtD
Alprostadil—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00105	0.011	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00105	0.0177	CbGpPWpGaD
Alprostadil—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00104	0.0108	CcSEcCtD
Alprostadil—Wheezing—Lisinopril—dilated cardiomyopathy	0.00104	0.0108	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—TTN—dilated cardiomyopathy	0.00101	0.017	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000992	0.0168	CbGpPWpGaD
Alprostadil—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000968	0.0101	CcSEcCtD
Alprostadil—Discomfort—Spironolactone—dilated cardiomyopathy	0.000962	0.0101	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—TTN—dilated cardiomyopathy	0.000958	0.0162	CbGpPWpGaD
Alprostadil—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000941	0.00982	CcSEcCtD
Alprostadil—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000914	0.00955	CcSEcCtD
Alprostadil—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000892	0.00931	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—ACTN2—dilated cardiomyopathy	0.000872	0.0147	CbGpPWpGaD
Alprostadil—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.000851	0.00889	CcSEcCtD
Alprostadil—Injury—Lisinopril—dilated cardiomyopathy	0.000844	0.00881	CcSEcCtD
Alprostadil—PTGER2—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000832	0.0141	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—ACTN2—dilated cardiomyopathy	0.000831	0.014	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000827	0.014	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000827	0.014	CbGpPWpGaD
Alprostadil—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000825	0.00862	CcSEcCtD
Alprostadil—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000806	0.00842	CcSEcCtD
Alprostadil—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000795	0.0083	CcSEcCtD
Alprostadil—Renal failure—Furosemide—dilated cardiomyopathy	0.000783	0.00818	CcSEcCtD
Alprostadil—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000776	0.0081	CcSEcCtD
Alprostadil—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00077	0.00804	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—VCL—dilated cardiomyopathy	0.000741	0.0125	CbGpPWpGaD
Alprostadil—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000738	0.00771	CcSEcCtD
Alprostadil—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000737	0.0077	CcSEcCtD
Alprostadil—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000727	0.00759	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—VCL—dilated cardiomyopathy	0.000706	0.0119	CbGpPWpGaD
Alprostadil—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000701	0.00732	CcSEcCtD
Alprostadil—Visual impairment—Furosemide—dilated cardiomyopathy	0.000689	0.0072	CcSEcCtD
Alprostadil—PTGIR—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.000676	0.0114	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000674	0.0114	CbGpPWpGaD
Alprostadil—Influenza—Lisinopril—dilated cardiomyopathy	0.00067	0.007	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—RAC1—dilated cardiomyopathy	0.000668	0.0113	CbGpPWpGaD
Alprostadil—Pruritus—Spironolactone—dilated cardiomyopathy	0.000661	0.0069	CcSEcCtD
Alprostadil—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000653	0.00682	CcSEcCtD
Alprostadil—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000645	0.00673	CcSEcCtD
Alprostadil—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000639	0.00667	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000623	0.00651	CcSEcCtD
Alprostadil—Erythema—Furosemide—dilated cardiomyopathy	0.000622	0.0065	CcSEcCtD
Alprostadil—Dizziness—Spironolactone—dilated cardiomyopathy	0.000618	0.00645	CcSEcCtD
Alprostadil—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000605	0.00632	CcSEcCtD
Alprostadil—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000598	0.00625	CcSEcCtD
Alprostadil—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000589	0.00615	CcSEcCtD
Alprostadil—Rash—Spironolactone—dilated cardiomyopathy	0.000589	0.00615	CcSEcCtD
Alprostadil—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000588	0.00614	CcSEcCtD
Alprostadil—Renal failure—Lisinopril—dilated cardiomyopathy	0.000588	0.00614	CcSEcCtD
Alprostadil—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000586	0.00612	CcSEcCtD
Alprostadil—Headache—Spironolactone—dilated cardiomyopathy	0.000585	0.00611	CcSEcCtD
Alprostadil—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000581	0.00607	CcSEcCtD
Alprostadil—Anaemia—Furosemide—dilated cardiomyopathy	0.000575	0.00601	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000575	0.00972	CbGpPWpGaD
Alprostadil—Haematuria—Lisinopril—dilated cardiomyopathy	0.00057	0.00595	CcSEcCtD
Alprostadil—PTGIR—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000562	0.0095	CbGpPWpGaD
Alprostadil—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000561	0.00586	CcSEcCtD
Alprostadil—Nausea—Spironolactone—dilated cardiomyopathy	0.000555	0.00579	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000547	0.00924	CbGpPWpGaD
Alprostadil—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000546	0.0057	CcSEcCtD
Alprostadil—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000538	0.00562	CcSEcCtD
Alprostadil—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000533	0.00556	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000532	0.00899	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000532	0.00899	CbGpPWpGaD
Alprostadil—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000526	0.00549	CcSEcCtD
Alprostadil—Dry mouth—Furosemide—dilated cardiomyopathy	0.000518	0.00541	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000518	0.00876	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000514	0.00869	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000504	0.00852	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000504	0.00852	CbGpPWpGaD
Alprostadil—Shock—Furosemide—dilated cardiomyopathy	0.0005	0.00522	CcSEcCtD
Alprostadil—Flushing—Lisinopril—dilated cardiomyopathy	0.000498	0.0052	CcSEcCtD
Alprostadil—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000497	0.00519	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000494	0.00836	CbGpPWpGaD
Alprostadil—Skin disorder—Furosemide—dilated cardiomyopathy	0.000493	0.00515	CcSEcCtD
Alprostadil—ABCC4—Ectoderm Differentiation—DMD—dilated cardiomyopathy	0.000493	0.00833	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000491	0.00513	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000478	0.00808	CbGpPWpGaD
Alprostadil—Hypotension—Furosemide—dilated cardiomyopathy	0.000475	0.00496	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000469	0.00792	CbGpPWpGaD
Alprostadil—Erythema—Lisinopril—dilated cardiomyopathy	0.000467	0.00488	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000463	0.00783	CbGpPWpGaD
Alprostadil—PTGIR—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000455	0.0077	CbGpPWpGaD
Alprostadil—Nervousness—Lisinopril—dilated cardiomyopathy	0.000454	0.00474	CcSEcCtD
Alprostadil—Back pain—Lisinopril—dilated cardiomyopathy	0.000452	0.00472	CcSEcCtD
Alprostadil—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000449	0.00469	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.000446	0.00754	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000441	0.00745	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000441	0.00745	CbGpPWpGaD
Alprostadil—Pain—Furosemide—dilated cardiomyopathy	0.000434	0.00454	CcSEcCtD
Alprostadil—Anaemia—Lisinopril—dilated cardiomyopathy	0.000432	0.00451	CcSEcCtD
Alprostadil—Syncope—Lisinopril—dilated cardiomyopathy	0.000419	0.00437	CcSEcCtD
Alprostadil—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000419	0.00437	CcSEcCtD
Alprostadil—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000411	0.00429	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00041	0.00692	CbGpPWpGaD
Alprostadil—Cough—Lisinopril—dilated cardiomyopathy	0.000408	0.00426	CcSEcCtD
Alprostadil—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000402	0.00419	CcSEcCtD
Alprostadil—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000402	0.00419	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000397	0.0067	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000395	0.00668	CbGpPWpGaD
Alprostadil—Discomfort—Lisinopril—dilated cardiomyopathy	0.000393	0.0041	CcSEcCtD
Alprostadil—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000389	0.00406	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.000387	0.00654	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TTN—dilated cardiomyopathy	0.000386	0.00652	CbGpPWpGaD
Alprostadil—Oedema—Lisinopril—dilated cardiomyopathy	0.000381	0.00398	CcSEcCtD
Alprostadil—Infection—Lisinopril—dilated cardiomyopathy	0.000379	0.00396	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000375	0.00634	CbGpPWpGaD
Alprostadil—Shock—Lisinopril—dilated cardiomyopathy	0.000375	0.00392	CcSEcCtD
Alprostadil—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000373	0.0039	CcSEcCtD
Alprostadil—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000372	0.00389	CcSEcCtD
Alprostadil—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00037	0.00387	CcSEcCtD
Alprostadil—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000369	0.00385	CcSEcCtD
Alprostadil—Asthenia—Furosemide—dilated cardiomyopathy	0.000365	0.00381	CcSEcCtD
Alprostadil—Pruritus—Furosemide—dilated cardiomyopathy	0.000359	0.00375	CcSEcCtD
Alprostadil—Hypotension—Lisinopril—dilated cardiomyopathy	0.000356	0.00372	CcSEcCtD
Alprostadil—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000348	0.00363	CcSEcCtD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000347	0.00587	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000347	0.00587	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000346	0.00584	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000339	0.00573	CbGpPWpGaD
Alprostadil—Dizziness—Furosemide—dilated cardiomyopathy	0.000336	0.00351	CcSEcCtD
Alprostadil—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000336	0.0035	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000335	0.00567	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000335	0.00567	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ACTN2—dilated cardiomyopathy	0.000334	0.00565	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.000329	0.00556	CbGpPWpGaD
Alprostadil—Pain—Lisinopril—dilated cardiomyopathy	0.000326	0.0034	CcSEcCtD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000323	0.00546	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000323	0.00546	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000321	0.00543	CbGpPWpGaD
Alprostadil—Rash—Furosemide—dilated cardiomyopathy	0.00032	0.00335	CcSEcCtD
Alprostadil—Dermatitis—Furosemide—dilated cardiomyopathy	0.00032	0.00334	CcSEcCtD
Alprostadil—Headache—Furosemide—dilated cardiomyopathy	0.000318	0.00332	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—CD36—dilated cardiomyopathy	0.000317	0.00537	CbGpPWpGaD
Alprostadil—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000314	0.00328	CcSEcCtD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000313	0.00529	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000313	0.00529	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000312	0.00527	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000309	0.00522	CbGpPWpGaD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—EGFR—dilated cardiomyopathy	0.000304	0.00513	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	0.000302	0.00511	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000302	0.00511	CbGpPWpGaD
Alprostadil—Nausea—Furosemide—dilated cardiomyopathy	0.000302	0.00315	CcSEcCtD
Alprostadil—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000301	0.00315	CcSEcCtD
Alprostadil—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000301	0.00315	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.0003	0.00508	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000298	0.00503	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000298	0.00503	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000298	0.00503	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000298	0.00503	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000292	0.00494	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000292	0.00494	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000287	0.00485	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VCL—dilated cardiomyopathy	0.000284	0.00481	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000279	0.00472	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000279	0.00472	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000277	0.00468	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000277	0.00468	CbGpPWpGaD
Alprostadil—Asthenia—Lisinopril—dilated cardiomyopathy	0.000273	0.00286	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000272	0.00459	CbGpPWpGaD
Alprostadil—Pruritus—Lisinopril—dilated cardiomyopathy	0.00027	0.00282	CcSEcCtD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000268	0.00453	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000268	0.00453	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000267	0.00451	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000267	0.00451	CbGpPWpGaD
Alprostadil—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000261	0.00272	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00026	0.00439	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000258	0.00436	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000253	0.00428	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000253	0.00428	CbGpPWpGaD
Alprostadil—Dizziness—Lisinopril—dilated cardiomyopathy	0.000252	0.00263	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000245	0.00414	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000243	0.00411	CbGpPWpGaD
Alprostadil—Rash—Lisinopril—dilated cardiomyopathy	0.00024	0.00251	CcSEcCtD
Alprostadil—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00024	0.00251	CcSEcCtD
Alprostadil—Headache—Lisinopril—dilated cardiomyopathy	0.000239	0.00249	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000238	0.00403	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TTN—dilated cardiomyopathy	0.00023	0.00389	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000229	0.00387	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000229	0.00387	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000227	0.00383	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000227	0.00383	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000227	0.00383	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000227	0.00383	CbGpPWpGaD
Alprostadil—Nausea—Lisinopril—dilated cardiomyopathy	0.000226	0.00236	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000217	0.00368	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000217	0.00367	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000217	0.00367	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000211	0.00356	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000211	0.00356	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000204	0.00345	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000204	0.00345	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ACTN2—dilated cardiomyopathy	0.000199	0.00337	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000199	0.00336	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000194	0.00327	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000194	0.00327	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00019	0.0032	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00019	0.0032	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000189	0.00319	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000182	0.00307	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00018	0.00304	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TAZ—dilated cardiomyopathy	0.000177	0.003	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000176	0.00298	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000174	0.00295	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000174	0.00295	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000172	0.00291	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000172	0.00291	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000171	0.00289	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VCL—dilated cardiomyopathy	0.00017	0.00287	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000165	0.00279	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000165	0.00279	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000161	0.00272	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000161	0.00272	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SDHA—dilated cardiomyopathy	0.00016	0.00271	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00016	0.00271	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000155	0.00262	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000151	0.00255	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000146	0.00246	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ITGB1—dilated cardiomyopathy	0.000143	0.00241	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000141	0.00238	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000138	0.00234	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000133	0.00224	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000132	0.00224	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000128	0.00216	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000128	0.00216	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000128	0.00216	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000128	0.00216	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000126	0.00212	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000123	0.00207	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000123	0.00207	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—CD36—dilated cardiomyopathy	0.000122	0.00206	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000119	0.00201	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000119	0.00201	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000116	0.00197	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000116	0.00197	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000116	0.00197	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000116	0.00197	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000115	0.00195	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000115	0.00195	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—RAC1—dilated cardiomyopathy	0.000115	0.00194	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000115	0.00194	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000108	0.00183	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000108	0.00183	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000108	0.00182	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000107	0.00181	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000105	0.00177	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000105	0.00177	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000103	0.00175	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000103	0.00173	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000102	0.00173	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000102	0.00172	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000102	0.00172	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.85e-05	0.00166	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.85e-05	0.00166	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NPPA—dilated cardiomyopathy	9.81e-05	0.00166	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.75e-05	0.00165	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PSEN2—dilated cardiomyopathy	9.5e-05	0.00161	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.46e-05	0.0016	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.34e-05	0.00158	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.34e-05	0.00158	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AGT—dilated cardiomyopathy	9.32e-05	0.00157	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.16e-05	0.00155	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.94e-05	0.00151	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.94e-05	0.00151	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	8.8e-05	0.00149	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ITGB1—dilated cardiomyopathy	8.51e-05	0.00144	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.48e-05	0.00143	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.48e-05	0.00143	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.82e-05	0.00132	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.74e-05	0.00131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.74e-05	0.00131	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—RAF1—dilated cardiomyopathy	7.61e-05	0.00129	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.42e-05	0.00125	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CD36—dilated cardiomyopathy	7.26e-05	0.00123	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.25e-05	0.00123	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.25e-05	0.00123	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.93e-05	0.00117	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.93e-05	0.00117	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.87e-05	0.00116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.87e-05	0.00116	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.87e-05	0.00116	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.87e-05	0.00116	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RAC1—dilated cardiomyopathy	6.84e-05	0.00116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.59e-05	0.00111	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.59e-05	0.00111	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.47e-05	0.00109	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.39e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.39e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.38e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGT—dilated cardiomyopathy	6.29e-05	0.00106	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGT—dilated cardiomyopathy	6.29e-05	0.00106	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.19e-05	0.00105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.19e-05	0.00105	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.93e-05	0.001	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RAC1—dilated cardiomyopathy	5.76e-05	0.000974	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.66e-05	0.000957	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGT—dilated cardiomyopathy	5.5e-05	0.00093	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.28e-05	0.000893	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.28e-05	0.000893	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.01e-05	0.000847	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.01e-05	0.000847	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RAC1—dilated cardiomyopathy	4.78e-05	0.000808	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RAF1—dilated cardiomyopathy	4.54e-05	0.000767	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.43e-05	0.000749	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.37e-05	0.000738	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.37e-05	0.000738	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—dilated cardiomyopathy	4.36e-05	0.000737	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.31e-05	0.000728	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.31e-05	0.000728	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CD36—dilated cardiomyopathy	4.25e-05	0.000718	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.93e-05	0.000664	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RAC1—dilated cardiomyopathy	3.89e-05	0.000658	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.89e-05	0.000658	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AGT—dilated cardiomyopathy	3.82e-05	0.000646	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.82e-05	0.000646	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGT—dilated cardiomyopathy	3.72e-05	0.000628	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGT—dilated cardiomyopathy	3.72e-05	0.000628	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RAF1—dilated cardiomyopathy	3.17e-05	0.000535	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.99e-05	0.000506	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.99e-05	0.000506	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.62e-05	0.000443	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RAF1—dilated cardiomyopathy	2.58e-05	0.000436	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.58e-05	0.000436	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—dilated cardiomyopathy	2.17e-05	0.000367	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—dilated cardiomyopathy	1.77e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.77e-05	0.000299	CbGpPWpGaD
